<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00361127</url>
  </required_header>
  <id_info>
    <org_study_id>CCM S65/206</org_study_id>
    <nct_id>NCT00361127</nct_id>
  </id_info>
  <brief_title>Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure</brief_title>
  <official_title>Influence of ACE Genotype on Lung Diffusion at Rest and After Fluid Overload in Heart Failure Patients Treated With ACE-inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Piergiuseppe Agostoni</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Cardiologico Monzino</source>
  <brief_summary>
    <textblock>
      In patients with chronic heart failure ACE-inhibitor treatment improves lung diffusion and
      prevents pulmonary edema after fluid overload. In the western country, 3 population types of
      ACE genotypes exist (DD, ID, II). It is unknown whether the ACE genotype influences the
      response to fluid overload in ACE-inhibitor treated chronic heart failure patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic heart failure in stable clinical condition treated with ACE-inhibitors,
      but not aspirin, will be evaluated by means of maximal cardiopulmonary exercise test and lung
      function including lung diffusion measurements. These tests will be done before and after
      rapid 500 ml isotonic saline infusion. Patients will be grouped according to their ACE
      genotype.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Possible identification of a genetic pattern responsible for different responses to ACE-inhibition during fluid overload in heart failure</measure>
    <time_frame>Third day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of ACE-genotype on exercise capacity</measure>
    <time_frame>Third day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of ACE-genotype on lung function</measure>
    <time_frame>Third day</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>CMPD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CMPD with evaluation of ACE I/D polymorphism</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotonic saline infusion</intervention_name>
    <arm_group_label>CMPD patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New York Heart Association (NYHA) class I and II heart failure

          -  Chronic ACE-inhibitor treatment

        Exclusion Criteria:

          -  Aspirin treatment in the previous 2 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piergiuseppe Agostoni, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Cardiologico Monzino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Agostoni P, Cattadori G, Bianchi M, Wasserman K. Exercise-induced pulmonary edema in heart failure. Circulation. 2003 Nov 25;108(21):2666-71. Epub 2003 Oct 27.</citation>
    <PMID>14581402</PMID>
  </reference>
  <reference>
    <citation>Guazzi M, Marenzi G, Alimento M, Contini M, Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation. 1997 Apr 1;95(7):1930-6.</citation>
    <PMID>9107182</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2006</study_first_submitted>
  <study_first_submitted_qc>August 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2006</study_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centro Cardiologico Monzino</investigator_affiliation>
    <investigator_full_name>Piergiuseppe Agostoni</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>pulmonary edema</keyword>
  <keyword>ACE-inhibitors</keyword>
  <keyword>lung diffusion</keyword>
  <keyword>exercise capacity</keyword>
  <keyword>Chronic heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

